Background {#Sec1}
==========

Human cells produce thousands of proteins that integrated into an extremely complex physiologic network perform precise actions as catalysers, signalling agents or structural components. Then, dysfunction of proteins with abnormal amino acid sequences or the absence of a given protein often results in the development of severe pathologies such as diabetes \[[@CR1]\], dwarfism \[[@CR2]\], cystic fibrosis \[[@CR3]\], thalassaemia \[[@CR4]\] or impaired blood clotting \[[@CR5]\], among many others \[[@CR6], [@CR7]\]. In the absence of standardized gene therapy treatments that would genetically reconstitute functional protein production within the patient, protein deficiencies must be treated by the punctual or repeated clinical administration of the missing protein, so as to reach ordinary functional concentrations. These therapeutic proteins are produced ex vivo mostly in biological systems \[[@CR8]\], which must guarantee not only full protein functionalities but also a cost-effective industrial fabrication and the absence of hazardous contaminants. Protein drugs have to necessarily conform to quality constrains stricter than those expected in the production of enzymes for chemical industries, which consequently defines the choice of recombinant hosts, protocols and production strategies. Nowadays, there are over 400 marketed recombinant products (peptides and proteins) and other 1300 are undergoing clinical trials (figures updated on May 2015 \[[@CR9]\]).

In this context of expanding protein drug markets, there is a generic consensus about the need to enable drugs for cell- or tissue-targeted delivery to reduce doses, production costs and side effects. While increasing protein stability in vivo can be reached by discrete modifications in the amino acid sequence, generating fusions between therapeutic proteins and specific peptide ligands or antibodies that interact with particular cell receptors might allow acquiring specificity in the delivery process. In this regard and also pushed by the convenience to combine diagnosis and therapy in theranostic agents \[[@CR10], [@CR11]\], contemporary research on protein pharmaceuticals tends towards engineered versions functionally more sophisticated than plain natural polypeptides.

Review {#Sec2}
======

Cell factories {#Sec3}
--------------

Since early recombinant DNA times, ever-increasing understanding of cell physiology and stress, and of factors involved in heterologous gene expression and protein production empowered the use of different living factories, namely prokaryotic and eukaryotic cells, plants or animals \[[@CR12], [@CR13]\]. By using these systems, recombinant production solves source availability problems, is considered a bio-safe and green process and confers the ability to modify amino acid sequences and therefore protein function, to better adjust the product to a desired function \[[@CR14]\]. There is a wide and growing spectrum of expression systems that are becoming available for the production of recombinant proteins \[[@CR15], [@CR16]\]. *Escherichia coli* was the prevalent platform when the biopharmaceutical sector emerged in the 1980s, and it was followed by the implementation of the yeast *Saccharomyces cerevisiae*. Both systems and the associated genetic methodologies exhibit an unusually high versatility, making them adaptable to different production demands \[[@CR17]\]. Despite the exploration of insect cells as initially successful system especially for vaccine-oriented proteins, mammalian cell lines (most notably CHO cells) are nowadays the prevailing animal-derived cell system due to their suitability to produce conveniently glycosylated proteins \[[@CR18], [@CR19]\] (Fig. [1](#Fig1){ref-type="fig"}). The ability to carry out post translational modifications contrasts with complex nutritional requirements, slow growth and fragility, and relatively high production timing and costs. Thus, among many conventional and emerging cell-based systems for protein production, bacteria, yeast and mammalian cell lines are the most common in biopharma, and both prokaryotic and eukaryotic systems are constantly evolving and competing to improve their properties and intensify as platforms of choice for protein drug production \[[@CR14]\]. While bacteria has lost its early leading role in the field \[[@CR19]\], about 30 % of marketed biopharmaceuticals are still produced in this system \[[@CR20]\], as supported by the unusual physiological and genetic manipulability of prokaryotic cells \[[@CR21]\].Fig. 1Number of recombinant protein products approved for use as drugs in humans, depending on the type of production platform

In fact, the main purpose in the development of new protein production platforms is to enhance drug functionality through reaching successful protein folding and post-translational modifications, while keeping the low complexity and high flexibility associated to prokaryotic cell culture. In this context, Gram-positive bacteria such as *Bacillus megaterium* \[[@CR22]\] and *Lactococcus lactis* \[[@CR23]\] allow efficient protein secretion in absence of endotoxic cell wall components, while filamentous fungi (such as *Trichoderma reesei*, \[[@CR24]\]), moss (*Physcomitrella patens*, \[[@CR25], [@CR26]\]) and protozoa (*Leishmania tarentolae*, \[[@CR27]--[@CR29]\]) promote glycosylation patterns similar to those in mammalian proteins but being still cultured through methods simpler than those required by mammalian cells. Extensive descriptions of emerging (bacterial and non-bacterial) platforms specifically addressed to the production of high quality protein drugs can be found elsewhere \[[@CR15], [@CR16], [@CR21]\]. The recent development of an endotoxin-free strain of *E. coli* \[[@CR30]\] and its application to the fabrication of proteins and protein materials \[[@CR30]--[@CR32]\] paves the road for a cost-efficient and versatile production of proteins intended for biomedical uses by skipping endotoxin removal steps, thus gaining in biosafety and reducing production costs \[[@CR33]\]. Hopefully, all these new systems would soon offer improved products in still simple and fully controlled biofabrication approaches.

Trends in protein biopharmaceuticals {#Sec4}
------------------------------------

Nearly 400 recombinant protein-based products have been successfully produced and are approved as biopharmaceuticals \[[@CR9]\], a term that refers to therapeutic products generated by technologies that involve living organisms \[[@CR34]\]. Other 1300 protein candidates are under development, of which around 50 % are in pre-clinical studies and other 33 % in clinical trials \[[@CR9]\] (Fig. [2](#Fig2){ref-type="fig"}). In this context, an increase in the number of approvals in next years is predictable. Developed by Eli Lilly & Co in the 70's, Humulin, a recombinant human insulin fabricated in the bacterium *E. coli* \[[@CR35]\], was the first approved biopharmaceutical (by the FDA) in 1982 \[[@CR36], [@CR37]\]. Other natural proteins such as hormones, cytokines and antibodies (Orthoclone OKT3) were among the single nine products approved in 1980s (Table [1](#Tab1){ref-type="table"}). Nowadays, the therapeutic areas that have benefited more from recombinant biopharmaceuticals are metabolic disorders (e.g. diabetes type 1, type 2, obesity or hypoglycaemia), haematological disorders (e.g. renal anaemia, haemophilia A, bleeding or clotting disorders) and oncology (e.g. melanoma, breast or colorectal cancer), with 24, 18 and 15 % of the approvals respectively (Fig. [3](#Fig3){ref-type="fig"}). In this regard, oncology is a clearly expanding market. In the period 2010--2014, 9 out of 54 approved biopharmaceuticals were antitumoral drugs, cancer representing the most common indication within this period. Digging into the molecular bases of biopharmaceuticals, there is a clear trend towards antibody-based products. Over the same period (2010--2014), 17 of the 54 protein drugs approved were monoclonal antibodies (31.5 %), compared with 11 % over 1980--1989 \[[@CR22]\]. Furthermore, among the top ten selling protein biopharmaceuticals globally in 2014 (Table [2](#Tab2){ref-type="table"}), six are antibodies or antibody-derived proteins (Humira, Remicade, Rituxan, Enbrel, Avastin, Herceptin; <http://qz.com/349929/best-selling-drugs-in-the-world/>).Fig. 2Workflow involved in the development of a new drugs and approximate percentage (*bars* and *numbers*) of recombinant proteins currently in each step \[[@CR9]\]Table 1Recombinant biopharmaceuticals approved in the 1980sProductCell factoryTherapeutic indicationYearHumulin*E. coli*Diabetes1982Protropin*E. coli*hGH deficiency1985Roferon A*E. coli*Hairy cell leukaemia1986IntronA*E. coli*Cancer, genital warts and hepatitis1986Recombivax*S. cerevisiae*Hepatitis B1986Orthoclone OKT3Hybridoma cell lineReversal of acute kidney and transplant rejection1986Humatrope*E. coli*hGH deficiency1987ActivaseCHOAcute myocardial infarction1987EpogenCHOAnaemia1989Fig. 3Amount of marketed recombinant proteins (expressed in percentages) applied to each therapeutic area. Coloured in pink, other therapeutic areas (\<5 % each) include diseases related to cardiology, central nervous system, ophthalmology and dermatology among othersTable 2Top ten selling protein biopharmaceuticals in 2014Drug^a^Active ingredientMoleculeSales in billionsOriginHumiraAdalimumabRecombinant human monoclonal antibody12.54CHOSovaldiSofosbuvirNucleotide analogue polymerase (NS5B) inhibitor10.28ChemicalRemicadeInfliximabRecombinant chimeric, humanized tumor necrosis factor alpha (TNF) monoclonal antibody9.24Hybridoma cell lineRituxanRituximabRecombinant humanized monoclonal antibody8.68CHOEnbrelEtanerceptRecombinant soluble dimeric fusion protein8.54CHOLantusInsulin glargineInsulin receptor agonist7.28*E. coli*AvastinBevacizumabRecombinant humanized antibody6.96CHOHerceptinTrastuzumabRecombinant humanized monoclonal antibody6.79CHOAdvairFluticasone propionate and salmeterol xinafoateGlucocorticoid receptor agonist and β-2 adrenergic receptor agonist6.43ChemicalCrestorRosuvastatin calciumAntihyperlipedemic agent5.87Synthetic^a^Data according to [www.medtrack.com](http://www.medtrack.com), November 2015

Formerly, biopharmaceuticals were recombinant versions of natural proteins, with the same amino acid sequence as the respective native versions (with only minor modifications, often resulting from the cloning strategy). Since 1990s, a meaningful proportion of the approvals are based on highly modified forms of recombinant proteins. This novel alternative, based on protein or domain fusion and on truncated versions, offers a wide spectrum of possible combinations to obtain novel biopharmaceuticals with different joined activities that are not found together in nature.

Protein drugs for cancer treatment {#Sec5}
----------------------------------

Oncology is one of the therapeutic indications that dominate the biopharmaceutical market, as cancer is a major cause of morbidity and mortality worldwide. Surgery and radiotherapy are effective in curing cancer at early disease stages; however, they cannot eradicate metastatic disease. The presence of micrometastases or clinically evident metastases at diagnosis requires their use in combination with genotoxic chemotherapy to increase cure rates \[[@CR38]\]. Nevertheless, the success of chemotherapy has been hampered because of its lack of selectivity and specificity, so that the toxicity to normal tissues limits the dose that could be administered to patients. The development of biopharmaceuticals capable of inhibiting specific molecular targets driving cancer (for instance, monoclonal antibodies anti-Her2---Trastuzumab- or anti-VEGF---Bevacizumab-) goes in this direction \[[@CR39]\].

Among marketed protein biopharmaceuticals, almost 24 % (94 products) are used in antitumoral therapies. Most of these products are used for supportive purposes intended to minimize the side effects of chemotherapy, usually neutropenia or anaemia (some representative examples are shown in Table [3](#Tab3){ref-type="table"}). Nineteen out of those 94 products are true antitumoral drugs, 69 % of which are produced in *E. coli* (Fig. [4](#Fig4){ref-type="fig"}) and are based on engineered amino acidic sequences, protein fusions and single protein domains (Table [4](#Tab4){ref-type="table"}).Table 3Representative examples of supportive protein drugs in cancerDrug nameCell factoryBiological roleMechanism of actionIndicationsFilgrastim (Scimax)*E. coli*CytokineStimulates hematopoiesisBone marrow transplantation and cancer chemotherapy induced neutropeniaPegfilgrastim (Neupeg)*E. coli*CytokineStimulates differentiation, proliferation and activation of the neutrophilic granulocytesCancer chemotherapy induced neutropeniaDarbepoetin alfa (Aranesp)CHO cellsHormoneStimulates processes of erythropoiesis or red blood cell productionAnemia associated with chronic renal failure, cancer chemotherapy or heart failure. Myelodysplastic syndromeLenograstim (CERBIOS)CHO cellsCytokineStimulates differentiation, proliferation and activation of neutrophilic granulocytesNeutropenia associated with cytotoxic therapy or bone marrow transplantationEpoetin alfa (Binocrit)CHO cellsHormoneStimulates production of oxygen carrying red blood cells from the bone marrowAnemia associated with chronic renal failure and cancer chemotherapy induced anemiaFig. 4Cell factories used for the production of recombinant biopharmaceuticals against cancer (expressed in percentages)Table 4Anticancer recombinant biopharmaceuticals approved until March 2015Drug nameCell factorySourceBiological roleIndicationsDenileukin diftitox*E. coli*Fusion proteinDiphtheria toxin fused to cytokineCutaneous T-cell lymphomaEndostatin*E. coli*ModifiedCollagen derivativeNon-small cell lung cancer, metastatic colorectal cancerAldesleukin*E. coli*ModifiedCytokineMetastatic renal cell carcinoma, metastatic melanoma, kidney cancer, angiosarcomaInterleukin-2*E. coli*ModifiedCytokineMetastatic melanoma, metastatic renal cell carcinomaFilgrastim*E. coli*ModifiedCytokineAcute lymphocytic leukaemia, solid tumourInterferon alpha-2a*E. coli*ModifiedCytokineAIDS-related Kaposi's sarcoma, follicular lymphoma, cutaneous T-cell lymphoma, melanoma, chronic myelocytic leukaemia, hairy cell leukaemia, renal cell carcinoma, kidney cancerInterferon alpha-2b*E. coli*ModifiedCytokineAIDS-related Kaposi's sarcoma, pancreatic endocrine tumour, melanoma, non-Hodgkin lymphoma, leukaemia, hairy cell leukaemia, renal cell carcinoma, multiple myeloma, CML, follicular lymphoma, melanomaInterferon alpha-1b*E. coli*ModifiedCytokineRenal cell carcinoma, hairy cell leukaemiaInterferon gamma-1a*E. coli*ModifiedCytokineKidney cancer, sezary syndrome, mycosis fungoidesTasonermin*E. coli*NaturalCytokineSoft tissue sarcomaMolgramostim*E. coli*ModifiedGrowth factorMyelodysplastic syndromeNartograstim*E. coli*ModifiedGrowth factorSolid tumourPalifermin*E. coli*FractionGrowth factorMetastatic renal cell carcinoma, metastatic melanomaSargramostim*S. cerevisiae*ModifiedGrowth factorAcute myelocytic leukaemiaZiv-afliberceptCHO cellsFusion proteinGrowth factor receptor fused to IgG1Metastatic colorectal cancerThyrotropin alphaCHO cellsModifiedHormoneThyroid cancerTrastuzumab biosimilarCHO cellsModifiedMonoclonal antibodyBreast cancer, gastric cancer, metastatic breast cancerRituximab biosimilarCHO cellsModifiedMonoclonal antibodyNon-Hodgkin lymphoma, chronic lymphocytic leukaemiaInterferon alphaHuman lymphoblastoid cellsModifiedCytokineAIDS-related Kaposi's sarcoma, multiple myeloma, non-Hodgkin lymphoma, CML, hairy cell leukaemia, renal cell carcinoma

Clearly, modified protein versions are the most abundant in cancer therapies over natural polypeptides. As relevant examples, Ziv aflibercept is a recombinant fusion protein produced in CHO cells used against colorectal cancer. It consists of portions of each Vascular Endothelial Growth Factor Receptors (VEGFR1 and VEGFR2) fused to the constant fraction (Fc) of a human IgG1 immunoglobulin (Fig. [5](#Fig5){ref-type="fig"}). This construct acts as a decoy by binding to VEGF-A, VEGF-B and placental growth factor (PlGF), which activate VEGFR. This trap hinders the interaction between the growth factors and the receptors, inhibiting the VEGF pathway which is involved in the angiogenic process \[[@CR40]\]. Denileukin diftitox is a recombinant protein composed of two diphtheria toxin fragments (A and B) and a human interleukin-2 (Fig. [5](#Fig5){ref-type="fig"}). Diphteria toxin is a potent exotoxin secreted by *Corynebacterium diphteriae*. Due to its peculiar structure, the whole complex, produced in *E. coli*, is capable of delivering a cytotoxic agent directly to a specific target. There are two main active blocks whose function is firstly to selectively deliver the biopharmaceutical (IL-2) and secondly cause cytotoxicity (toxin A and B) \[[@CR41]\]. The fusion protein binds to the IL-2 receptor, which is expressed in cancerous cells (cutaneous T cell lymphoma). Once the toxin moiety is internalized, the catalytic domain promotes cell death through protein synthesis inhibition \[[@CR42]\].Fig. 5Schematic molecular structure of two marketed recombinant biopharmaceuticals

As targeted drug delivery for cancer is a most recent and expanding area of research, other non-recombinant, protein-based biopharmaceuticals are also heavily represented. Those mainly include antibody-drug conjugates (ADCs) such as Brentuximab vedotin, Trastuzumab emtansine, or nanoparticle-drug conjugates such as nab-paclitaxel \[[@CR39], [@CR43]\]. In these cases, the protein counterpart acts as a targeted vehicle for conventional chemical drugs. Again, this approach pursues the selective drug delivery to specific target cells, aimed to increase antitumoral activity while reducing toxicity on normal cells and the associated side effects.

Products against cancer that provided the highest revenues in 2013 are represented in Fig. [6](#Fig6){ref-type="fig"}. Sixty percent of those products are recombinant proteins, supporting the idea that recombinant protein production is still a rising and promising platform, offering room for important advances in the biopharmaceutical sector.Fig. 6Income provided by recombinant (*top*) and chemical drugs (*bottom*) against cancer in 2013. Figures according to Global Data \[[@CR9]\]

Conclusions {#Sec6}
===========

In summary, the market and potential for recombinant drugs is expanding by taking advantage of a steady growing spectrum of protein production platforms. Despite the strength of mammalian cell lines as factories, microbial cells and specially *E. coli* are still potent protein factories essentially supported by their versatility and cost-effective cultivation. Recombinant drugs are moving from plain recombinant versions of natural products to more sophisticated protein constructs resulting from a rational design process. Combining protein domains to gain new functionalities is being exploited in drug discovery by exploiting the structural and functional versatility that merge in proteins as extremely versatile macromolecules.
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